Sanofi Contingent Value Rights
GCVRZ
GCVRZ was delisted on the 3rd of March, 2020.
105 hedge funds and large institutions have $57.4M invested in Sanofi Contingent Value Rights in 2017 Q4 according to their latest regulatory filings, with 10 funds opening new positions, 15 increasing their positions, 15 reducing their positions, and 15 closing their positions.
6% more capital invested
Capital invested by funds: $54.3M → $57.4M (+$3.12M)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
0% more repeat investments, than reductions
Existing positions increased: 15 | Existing positions reduced: 15
5% less funds holding
Funds holding: 111 → 105 (-6)
33% less first-time investments, than exits
New positions opened: 10 | Existing positions closed: 15
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SCM
Stonehill Capital Management
New York
|
+$1.37M |
| 2 |
HCM
Highbridge Capital Management
New York
|
+$948K |
| 3 |
WC
Wexford Capital
West Palm Beach,
Florida
|
+$190K |
| 4 |
NGA
New Generation Advisors
Manchester,
Massachusetts
|
+$163K |
| 5 |
JGC
J. Goldman & Co
New York
|
+$75.9K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
TAM
TFG Asset Management
Grand Cayman,
Cayman Islands
|
-$961K |
| 2 |
Citigroup
New York
|
-$590K |
| 3 |
AFM
Anson Funds Management
Dallas,
Texas
|
-$540K |
| 4 |
Millennium Management
New York
|
-$180K |
| 5 |
WA
Whitebox Advisors
Minneapolis,
Minnesota
|
-$85.5K |
GCVRZ Hedge Fund Activity: Q4 2017 in Review
105 of the 4,409 institutional investors tracked by Wall St. Rank reported a position in Sanofi Contingent Value Rights (GCVRZ) for Q4 2017, worth a combined $57.4M — up 5.8% from $54.3M a quarter earlier.
Sellers outnumbered buyers: 15 funds closed out of GCVRZ and 10 opened new positions — a net loss of 5 holders — while 15 trimmed existing stakes and 15 added.
The largest buyer was Stonehill Capital Management, adding an estimated $1.37M. The largest seller was TFG Asset Management, exiting entirely with an estimated $961K sold.
- 105 institutional investors held Sanofi Contingent Value Rights (GCVRZ) as of Q4 2017, down from 111 in Q3 2017.
- Funds reported $57.4M of Sanofi Contingent Value Rights stock for Q4 2017, up 5.8% quarter-over-quarter.
- 10 funds opened new Sanofi Contingent Value Rights positions in Q4 2017 and 15 closed out, a net change of -5 holders.
- The largest Sanofi Contingent Value Rights buyer in Q4 2017 was Stonehill Capital Management, an estimated $1.37M added.
- The largest Sanofi Contingent Value Rights seller in Q4 2017 was TFG Asset Management, an estimated $961K sold.
Based on aggregated 13F filings for Q4 2017.